Brian Lowes, MD
Advanced Heart Failure and Transplant Cardiology · Omaha, NENPI 1518057298
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (26.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abbott accounts for 93.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $10,320 and has fallen 93.8% since, to $635 in 2025.
Across 159 payments — averaging $145.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$22K
- Transmedics, Inc.$439
- Medtronic$295
- Novartis$212
- Abiomed$157
- Bayer$140
- plus $302 from 6 others
Across 1 payment — averaging $548.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$548
What the payments were for
- Consulting fees$5,82425%
- Speaking & faculty fees$5,09622%
- Travel & lodging$6,04426%
- Food & beverage$6,18527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 127 | $21,604 |
| Transmedics, Inc. | 1 | $439 |
| Medtronic(2 entities) | 5 | $295 |
| Novartis | 13 | $212 |
| Abiomed | 2 | $157 |
| Bayer | 2 | $140 |
| Cvrx, Inc. | 1 | $137 |
| Impulse Dynamics (USA) Inc. | 2 | $59 |
| Pfizer | 3 | $47 |
| AstraZeneca | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate$9,464
- HeartMate 3 Left Ventricular Dev$2,172
- HeartMate PHP$1,458
- HeartMate II LVAS$1,411
- HeartMate 3 Left Ventricular Assist Device$1,173
- Ensite Cardiac Mapping System$1,160
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,131
- CARDIOMEMS$454
- ORGAN CARE SYSTEM$439
- MitraClip$151
- Impella$139
- HeartWare HVAD$138
- Barostim Neo System$137
- Adempas$125
- CardioMEMS HF System$121
How this compares
Too few advanced heart failure and transplant cardiology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 59 | $36,753 |
| EntrestoSacubitril/Valsartan | 20 | $31,914 |
| EliquisApixaban | 26 | $28,186 |
| JardianceEmpagliflozin | 16 | $22,546 |
| FarxigaDapagliflozin Propanediol | 19 | $15,162 |
| Sirolimus | 31 | $12,097 |
| Tacrolimus | 141 | $11,614 |
| Mycophenolate Mofetil | 97 | $7,452 |
| XareltoRivaroxaban | 14 | $6,869 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $1,805 |
| Pravastatin Sodium | 123 | $1,660 |
| Omega-3 Acid Ethyl Esters | 15 | $1,469 |
| Eplerenone | 12 | $1,347 |
| Rosuvastatin Calcium | 109 | $1,334 |
| Potassium Chloride | 31 | $1,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $212 | $31,91420 claims |
| PfizerEliquis | $47 | $28,18626 claims |
| AstraZenecaFarxiga | $22 | $15,16219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Omaha
- Scott LundgrenOmaha$179K
- Douglas StollerOmaha$53K
- Selma MohammedOmaha$34K
- Jason ColeOmaha$155
- Arif AlbulushiBellevue$51K
- Mathue BakerLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.